-- 据彭博社周三援引知情人士报道，索尼集团（SONY）旗下的索尼音乐即将达成协议，从黑石集团（BX）手中收购包括贾斯汀·比伯和尼尔·杨等艺人作品在内的音乐版权库。 报道称，索尼正与新加坡主权财富基金GIC洽谈，计划通过合资企业收购Recognition Music，GIC将支付35亿至40亿美元。 知情人士告诉彭博社，双方的目标是在下周完成交易，但能否最终达成尚无定论。 索尼尚未回复的置评请求。 周三下午交易中，索尼股价上涨超过3%。 （市场动态新闻来源于与全球市场专业人士的对话。我们认为这些信息来自可靠来源，但可能包含传闻和猜测。准确性无法保证。）
Price: $20.74, Change: $+0.61, Percent Change: +3.06%
Aptiv (APTV) stock sell-off post Q1 results was unwarranted and likely driven by the lower-than-expected Q2 guide and rising cost pressures with 2026 more back-half weighted that appears like a steep ramp, UBS said in a Wednesday research report.While Q2 is impacted by "stranded cost" and Ford Motor (F) volume timing, H2 ramp looks more achievable than optics suggest amid positive developments in China and the non-auto segments, analysts wrote.The company expects positive growth from China in Q2, driven by new programs and normalization of production at key customer, the brokerage stated.Commodity headwinds should abate in H2 as recoveries lag, UBS said.The brokerage said it reiterated its buy rating on the stock and price target of $80 per share.Aptiv shares were up 4% in Wednesday trading.Price: $56.47, Change: $+1.64, Percent Change: +2.99%
Price: $15.79, Change: $-4.34, Percent Change: -21.55%
Ocular Therapeutix (OCUL) is moving closer to a potential US Food and Drug Administration filing for axpaxli, its long-acting treatment for wet age-related macular degeneration, as regulators begin formal discussions on a single-trial approval path, RBC Capital Markets said Tuesday in a report.Management said talks with the FDA are now ongoing, raising the possibility of submitting an application based on the company's successful pivotal study, rather than waiting for a second trial that is due to read out in early 2027, RBC said.The company plans to provide additional regulatory and program updates at an investor day on June 17, RBC said.Ocular continues to target a potential 2027 launch for axpaxli under a single-trial filing strategy, and RBC reiterated its view that the drug has a "positive benefit/risk profile."RBC maintained its rating of outperform, speculative risk, on Ocular stock with a $30 price target.Price: $9.84, Change: $+0.13, Percent Change: +1.29%